Emerging Advances in Solid Tumor Immunotherapy: A Comparative Review of CAR-T, CAR-NK, CAR-M, and TIL Therapies

• 발행기관: 대한약학회
• 저자명: DaSeuRi Cha Chae-Min Lim KyuBum Kwack Jung Eun Park
• 간행물 정보: 『약학회지』제69권 제3호(2025년), 212~223쪽, 전체 12쪽
• 주제분류: 의약학 > 기타의약학
• 파일형태: PDF
• 발행일자: 2025.06.30

국문 초록

Solid tumors pose persistent challenges to cellular immunotherapy due to an immuno-suppressive tumor microenvironment and antigenic heterogeneity. While chimeric antigen receptor T cell (CAR-T) therapy has demonstrated remarkable success in hematologic malignancies, its effectiveness in solid tumors remains hindered by limited tumor infiltration, antigen escape, and immune evasion. To overcome these barriers, next-generation strategies—such as CARengineered natural killer (CAR-NK) cells, CAR-macrophages (CAR-M), and tumor-infiltrating lymphocyte (TIL) therapies—have emerged as innovative approaches. Each of these platforms offers distinct advantages: CAR-T cells provide potent cytotoxicity; CAR-NK cells leverage innate immune responses with a lower risk of graft-versus-host disease; CAR-M actively reshape the tumor microenvironment; and TILs enhance the persistence and infiltration of effector lymphocytes. Ongoing clinical trials underscore the rapid evolution of the therapeutic landscape, propelled by advancements in cell engineering and a deeper understanding of tumor immunobiology. While challenges remain, these emerging therapies represent promising avenues for achieving durable responses in solid tumors.

목차

Introduction

Overview of Cellular Therapies for Solid Tumors

Clinical Trial Landscape of Engineered Immune Cell Therapies in Solid Tumors

Challenges and Future Perspectives

Conclusion

Acknowledgment

Conflict of Interest

References

키워드

CAR-T CAR-NK CAR-M TIL Solid tumors Immunotherapy Tumor microenvironment Cellular therapy engineering